Search In this Thesis
   Search In this Thesis  
العنوان
Expression of programmed death ligand1 (pd-l1) in gastric carcinoma :
المؤلف
Safa Mohammed Ali AL.Azab,
هيئة الاعداد
باحث / Safa Mohammed Ali AL.Azab
مشرف / Dina Omar Helmy
مشرف / Dina Omar Helmy
مشرف / Hanan Soliman AbdelHamid
الموضوع
Gastric carcinoma
تاريخ النشر
2022.
عدد الصفحات
131 p. :
اللغة
الإنجليزية
الدرجة
الدكتوراه
التخصص
علم الأمراض والطب الشرعي
تاريخ الإجازة
1/1/2022
مكان الإجازة
جامعة القاهرة - كلية الطب - Pathology
الفهرس
Only 14 pages are availabe for public view

from 141

from 141

Abstract

Background: In Egypt, gastric cancer (GC) is the 12th most prevalent cancer
overall for both sexes. It is the fifth most common cancer globally and the third
main cause of cancer mortality. Strategies for cancer immunotherapy have been
created based on understanding of the interactions between the immune system
and cancer. Immune checkpoint regulators are among the most crucial of these
tactics. One important immune response checkpoint and a target for cancer
immunotherapy is the programmed death (PD) 1 pathway. Anti-PD-L1
antibodies have been effective in clinical trials for treating a variety of
malignancies. The Food and Drug Administration (FDA) has approved the
clinical use of certain of these antibodies.
Objectives: Detection of immunohistochemical (IHC) expression of PD-L1 by
tumor cells (TC), tumor infiltrating lymphocytes (TILs) and combined positive
score (CPS) in gastric cancer. Investigation of the possibility of using it as a
targeted therapy, as well as, correlation of this expression with the clinicopathologic parameters of the tumors.
Materials and methods: Gastrectomy specimens were used to collect 60 GC
tissue slices. In TC, TILs, and CPS, PD-L1 IHC expression was studied.
Results: TC PD-L1 expression was detected in 56.7% of cases, TILs PD-L1
expression was detected in 53.3 % of cases and CPS PD-L1 expression was
detected in 63.3% of case, with No statistically significant correlation with
clinico-pathological parameters except TILs PD-L1 expression showed
statistically significant correlation with positive TILs (P value ˂0.019).
Conclusion: Our findings supported the expression of PD-L1 by TC, TILs, and
CPS in gastric cancer, with increased expression in a subpopulation of TILs rich
in PD-L1 identifying them as potential targets for PD-1/PD-L1 therapy.